A Multicenter, Prospective, Randomized, Double Blind, Placebo Controlled, Adaptive Design Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of Venous Leg Ulcers (VALUE)
Latest Information Update: 25 Dec 2024
Price :
$35 *
At a glance
- Drugs EscharEx (Primary)
- Indications Leg ulcer; Varicose ulcer; Wounds
- Focus Adverse reactions; Registrational
- Acronyms VALUE
- Sponsors MediWound
- 17 Dec 2024 According to a MediWound media release, company announced it will host a virtual Key Opinion Leader (KOL) event on Wednesday, January 8, 2025, at 10:00 AM ET. The event will focus on EscharEx, an innovative biologic drug in late-stage clinical development for chronic wound debridement, including the upcoming Phase III VALUE study in venous leg ulcersand EscharExs commercial opportunity.
- 26 Aug 2024 Status changed from planning to not yet recruiting.
- 29 May 2024 According to a MediWound media release, Phase III trial remains on track for final protocol submission in the first half of 2024. The global study aims to enroll 216 patients across 40 sites to be treated with either EscharEx or a gel vehicle placebo. An interim assessment will be performed once 67% of participants complete the trial. The study is expected to commence in the second half of 2024.